Winette van der Graaf, President of the EORTC and Professor of Medical Oncology at The Netherlands Cancer Institute, shared a post on LinkedIn:
“The optimal way of getting answers with the highest level of evidence to questions on treatment optimisation (e.g. regarding dose and duration) is still in the context of a randomised clinical trial, a pragmatic one, like DE-ESCALATE in prostate cancer.
There are however challenges and hurdles with these kind of patient- centric trials, which require solutions.
Citing the Highlights of the paper:
-The EU Clinical Trial Regulation is not fully fit for public health clinical trials.
-Pragmatic clinical trials should be considered for treatment optimisation.
-The regulatory frameworks should be tailored for pragmatic clinical trials.
-Public health clinical trials facilitate optimal access to treatments.
For all those interested in this important topic I can recommend this paper from EORTC – European Organisation for Research and Treatment of Cancer highly.”
Title: Convergence of science, regulations and society in cancer clinical research: A perspective based on the EORTC DE-ESCALATE Study
Authors: Denis Lacombe, Fabio Borges, Stephanie Kromar, Bertrand Tombal
More posts featuring EORTC on OncoDaily.